
Adam Friedman, MD, FAAD
Dr. Friedman is Professor and Interim Chair of Dermatology and serves as Residency Program Director, Director of Translational Research and Director of the Supportive Oncodermatology Program in the Department of Dermatology at The George Washington University School of Medicine & Health Sciences. He graduated with Distinction in Dermatologic Research at the Albert Einstein College of Medicine in New York. Dr. Friedman is currently investigating novel nanotechnologies that allow for controlled and sustained delivery of a wide spectrum of physiologically and medicinally relevant molecules with an emphasis on treating infectious diseases, accelerating wound healing, immune modulation and correcting vascular dysfunction. He holds multiple patents derived from these investigations and has published over 170 papers/chapters and two textbooks on both his research as well as a variety of clinical areas in dermatology with an emphasis on emerging medical therapies, including various cannabinoids. He has received multiple awards and has been on the Washingtonian Top Doctors list since 2017. Dr. Friedman’s clinical interests span the gamut of medical and pediatric dermatology. He is frequently cited as an expert in the potential application of cannabinoid-based therapies to dermatologic disease.